(Q44723864)

5 December 2017

Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT. (English)

1 reference

5 December 2017

1 reference

6

Rodolfo Montironi

1 reference

5 December 2017

1

Kenneth A Iczkowski

1 reference

5 December 2017

Wei Huang

2

1 reference

5 December 2017

Roberta Mazzucchelli

series ordinal

3

1 reference

5 December 2017

Cooley G Pantazis

series ordinal

4

1 reference

5 December 2017

Gary R Stevens

series ordinal

5

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

5 December 2017

1 reference

5 December 2017

100

1 reference

5 December 2017

294-299

1 reference

5 December 2017

2

1 reference

bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer

5 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

Detection of telomerase activity in prostatic fluid specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Expression-patterns of the RNA component (hTR)and the catalytic subunit (hTERT) of human telomerase in nonneoplastic prostate tissue, prostatic intraepithelial neoplasia, and prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Gleason score predicts androgen independent progression after androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Focal intratumoral heterogeneity for telomerase activity in human prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Androgen depletion activates telomerase in the prostate of the nonhuman primate, Macaca mulatta.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Effects of androgens on telomerase activity in normal and malignant prostate cells in vitro.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

The effects of natural ligands of hormone receptors and their antagonists on telomerase activity in the androgen sensitive prostatic cancer cell line LNCaP.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Expression of the RNA component of human telomerase (hTR) in prostate cancer, prostatic intraepithelial neoplasia, and normal prostate tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

The RNA component of human telomerase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20002

7 January 2021

Identifiers

DOI

10.1002/CNCR.20002

1 reference

5 December 2017

1 reference